派博傳思國際中心

標題: Titlebook: Antibacterials; Volume I Jed F. Fisher,Shahriar Mobashery,Marvin J. Miller Book 2018 Springer International Publishing AG, part of Springer [打印本頁]

作者: 過分愛國主義 時間: 2025-3-21 16:41
書目名稱Antibacterials影響因子(影響力)

書目名稱Antibacterials影響因子(影響力)學科排名

書目名稱Antibacterials網絡公開度

書目名稱Antibacterials網絡公開度學科排名

書目名稱Antibacterials被引頻次

書目名稱Antibacterials被引頻次學科排名

書目名稱Antibacterials年度引用

書目名稱Antibacterials年度引用學科排名

書目名稱Antibacterials讀者反饋

書目名稱Antibacterials讀者反饋學科排名

作者: Lipoprotein 時間: 2025-3-21 21:46

作者: LVAD360 時間: 2025-3-22 02:25

作者: 良心 時間: 2025-3-22 06:34
Einführung in die Qualitative Marktforschungm of how pathogen-specific antibiotics can be developed is explored. The goal of this chapter is simply to familiarize the bench scientist with the challenges ahead for any project and to provide a framework for assessing risk in that context.

作者: Dappled 時間: 2025-3-22 11:34

作者: Respond 時間: 2025-3-22 15:22
The Clinical Development of Antibacterial Drugs: A Guide for the Discovery Scientist,m of how pathogen-specific antibiotics can be developed is explored. The goal of this chapter is simply to familiarize the bench scientist with the challenges ahead for any project and to provide a framework for assessing risk in that context.

作者: BADGE 時間: 2025-3-22 18:19

作者: Constitution 時間: 2025-3-23 01:12

作者: troponins 時間: 2025-3-23 01:31

作者: Contracture 時間: 2025-3-23 06:19
The Antibiotic Future,cterial pathogens, referred to here as antibiotics? What role will these small-molecule antibiotics have in the control of the bacterial infections of the future? Although there is today increased activity in the field of new antibiotic discovery, the history of this field over the past 30?years is

作者: constitute 時間: 2025-3-23 11:55
Synergistic Antibiotic Combinations,n the two are combined. Because of increasing antibiotic resistance, and few new drugs to treat multidrug-resistant bacteria, combination therapy is often used in the clinical setting. Frequently, these combinations have demonstrated synergistic activity both in vitro and in animal models before bei

作者: Emmenagogue 時間: 2025-3-23 14:42

作者: vanquish 時間: 2025-3-23 18:20

作者: stratum-corneum 時間: 2025-3-24 00:22
The Clinical Development of Antibacterial Drugs: A Guide for the Discovery Scientist,opment process. To meet this challenge, an innovator must have a basic understanding of those steps in this process that demand far more than knowledge of basic bench science. Perhaps the most difficult of these steps involves an understanding of regulatory and clinical development issues that only

作者: 帶傷害 時間: 2025-3-24 03:57
Four Ways to Skin a Cat: Inhibition of Bacterial Topoisomerases Leading to the Clinic,st through Phase 2 clinical trials. Compounds from each of the four classes are not cross-resistant to one another as determined by analyses with laboratory and clinical resistant bacterial strains. Hence, they are defined herein as sharing a mode of action, in that they inhibit the same targets, bu

作者: 防銹 時間: 2025-3-24 07:11
Book 2018hroughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known

作者: 和平主義者 時間: 2025-3-24 11:15

作者: micronized 時間: 2025-3-24 17:08
Philosophisch-psychologische Vorbemerkungen,lly with no clinical data to support their use. Because combination therapy will continue to be used in the absence of supportive clinical data, it will be important in the future to investigate mechanistic principles that may lead to predictive models for successful patient outcomes.

作者: investigate 時間: 2025-3-24 20:22

作者: CT-angiography 時間: 2025-3-25 03:12

作者: Arrhythmia 時間: 2025-3-25 04:14
1862-2461 teractions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known978-3-030-09821-6978-3-319-68097-2Series ISSN 1862-2461 Series E-ISSN 1862-247X

作者: malapropism 時間: 2025-3-25 09:43
The Antibiotic Future,tly grapple with the key scientific challenges that prevent forward motion. The future fate of antibiotic discovery will depend upon the degree to which the rate limiting steps of discovery are fully recognized, and the discovery technology turns to overcoming these blockades.

作者: 口味 時間: 2025-3-25 11:49
Synergistic Antibiotic Combinations,lly with no clinical data to support their use. Because combination therapy will continue to be used in the absence of supportive clinical data, it will be important in the future to investigate mechanistic principles that may lead to predictive models for successful patient outcomes.

作者: 彎曲的人 時間: 2025-3-25 19:15

作者: Ascendancy 時間: 2025-3-25 23:27

作者: 收藏品 時間: 2025-3-26 00:58

作者: 胎兒 時間: 2025-3-26 04:18
Topics in Medicinal Chemistryhttp://image.papertrans.cn/a/image/158395.jpg

作者: 賞錢 時間: 2025-3-26 11:48

作者: Transfusion 時間: 2025-3-26 13:15
https://doi.org/10.1007/978-3-642-49191-7cterial pathogens, referred to here as antibiotics? What role will these small-molecule antibiotics have in the control of the bacterial infections of the future? Although there is today increased activity in the field of new antibiotic discovery, the history of this field over the past 30?years is

作者: Density 時間: 2025-3-26 16:47